CAR-T Meeting 2022 | CAR-T as a second-line therapy in the lymphoma treatment landscape
Ulrich Jäger, MD, Medical University of Vienna, Vienna, Austria, gives an overview on the current and future use of chimeric antigen receptor T-cell (CAR-T) therapy in the lymphoma treatment landscape, focusing on the use of CAR-T as a second-line therapy in relation to autologous stem cell transplant, and which direction to take with other aggressive indications. Dr Jäger mentions the already approved use of CAR-T for mantle cell lymphoma (MCL) and its future use in follicular lymphoma (FL) and multiple myeloma. To conclude, Dr Jäger highlights the promising results obtained from CAR-T therapy in real-world settings, drawing focus on axicabtagene ciloleucel (axi-cel) and tisagenlecleucel (tisa-cel). This interview took place at the EBMT-EHA 4th European CAR T-cell Meeting which was held virtually in 2022.
Transcript (edited for clarity)
There are a lot of things going on in the CAR-T field. We’ve seen very interesting developments at the ASH meeting and will see more exciting things at the upcoming EHA-EBMT meeting. I think regarding the aggressive and foremost, the standard indications, the most interesting question will be where in relation to autologous stem cell transplant, the second-line indication will come in. I will comment on that maybe a bit later...
There are a lot of things going on in the CAR-T field. We’ve seen very interesting developments at the ASH meeting and will see more exciting things at the upcoming EHA-EBMT meeting. I think regarding the aggressive and foremost, the standard indications, the most interesting question will be where in relation to autologous stem cell transplant, the second-line indication will come in. I will comment on that maybe a bit later.
The other interesting question of course, is where do we go with other indications? We will have approvals and routine use soon for follicular lymphoma. We already have used for mantle cell lymphomas. We have seen at ASH, a number of real-world evidence in many different aggressive lymphoma indications, in CNS lymphomas, in post-transplant lymphomas. We’ve seen real-world data that look quite well. We’ve also seen, and I think that was one of the most remarkable real-world experiences, the French data on the current licensed indication in third-line diffuse large B-cell lymphomas, where they showed an update on both tisa-cel and axi-cel and their selection of patients, which seem to work quite well. And of course, let’s not forget that we will have the possibility to use CARs pretty soon in multiple myeloma.
Read more...
